DFFN - Diffusion to undertake strategic review options may include company sale

• Diffusion Pharmaceuticals ( NASDAQ: DFFN ) said it will undertake a strategic review to evaluate options which could include a sale of the company.
• As part of its ongoing efforts to identify acquisition and partnership transactions which complement its development programs and boost shareholder value, the board decided to expand its evaluation to a broader range of options, the company said in a press release on Tuesday.
• Diffusion will evaluate options which could include a joint venture, licensing, sale of some of its proprietary technologies or a sale of the company.
• The company has retained Canaccord Genuity as financial advisor and Dechert as legal counsel to help in the review process.
• Diffusion noted that there is no timeline for the review and there is no assurance that the board's review will lead to in any transaction.

For further details see: